AURA

Aura Biosciences, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001501796
$6.41 +3.22% $662.7M
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)6 New Institutional Positions6 Institutional Exits
Vol
Market Cap$662.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$116.1M
Inst. Activity6 buys / 6 sells
Insider Activity0B / 7S
Insider Net $-$39.7M
SEC Reports5
Press Releases6
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001501796·Prev Close $6.21

Recent Activity

May 19, 2026 Press
Aura Biosciences granted inducement equity awards to new CEO Natalie Holles, consisting of stock options, RSUs, and perf
Impact 3/10
May 19, 2026 regulatory
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com
May 19, 2026 Insider
Holles Natalie C. was granted 600,118 shares
See Remarks
May 19, 2026 Insider
Holles Natalie C. was granted 2,169,103 shares
See Remarks
May 7, 2026 Insider
Matrix Capital Management Company, LP sold 6,922,870 shares
10%+ Owner @ $5.64 ($39.0M)
May 5, 2026 SEC
Aura Biosciences priced a massive underwritten public offering of 46.1M shares of common stock and pre-funded warrants f
8-K — Impact 7/10
May 4, 2026 SEC
Aura Biosciences announced a stock repurchase agreement with Matrix Capital to buy back up to 6.9M shares at $5.64/share
8-K — Impact 5/10
May 4, 2026 SEC
Aura Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-f
424B5 — Impact 6/10

Price Targets

$18.80 +193.3% upside Strong Buy
Current $6.41 Low $15.00 Median $17.00 High $24.00 5 analysts
$15.00 $24.00

Analyst Ratings

Strong Buy92% buy · 12 analysts
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 29, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Mar 30, 2026 HC Wainwright & Co. REITERATE Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.38 ▲ +7.4% $-0.50 — $-0.30 20% YoY 4
Next Q $-0.37 ▲ +6.4% $-0.50 — $-0.30 8% YoY 4
Current FY $-1.59 $-2.00 — $-1.41 9% YoY 4
Next FY $-1.67 ▼ -2.3% $-1.91 — $-1.35 -5% YoY 4

Latest Reports

NEUTRAL Press 3/10
Aura Biosciences granted inducement equity awards to new CEO Natalie Holles, consisting of stock options, RSUs, and perf
May 19, 2026
BEARISH 8-K 7/10
Aura Biosciences priced a massive underwritten public offering of 46.1M shares of common stock and pre-funded warrants f
May 5, 2026
NEUTRAL 8-K 5/10
Aura Biosciences announced a stock repurchase agreement with Matrix Capital to buy back up to 6.9M shares at $5.64/share
May 4, 2026

Top Institutional Holders

FundValueMove
ADAGE CAPITAL PARTNERS GP,$32.7M—
BlackRock, Inc.$24.0M—
VANGUARD CAPITAL MANAGEMENT LLC$15.0M—
FRANKLIN RESOURCES INC$13.9MADD
STATE STREET CORP$6.5M—

Recent Insider Trades

DateInsiderTypeValue
May 19, 2026Holles NatalieA$0.00
May 19, 2026Holles NatalieA$0.00
May 7, 2026Matrix CapitalSELL$39.0M
Apr 16, 2026Kilroy ConorSELL$82.4K
Mar 2, 2026Kilroy ConorA$0.00
50 institutional holders with $116.1M total value (17,775,396 shares) as of 2026-Q1. Top holders: ADAGE, BlackRock,, VANGUARD.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ADAGE CAPITAL PARTNERS GP, L.L.C.4,881,125$32.7M28.1%—
2BlackRock, Inc.3,586,640$24.0M20.7%—
3VANGUARD CAPITAL MANAGEMENT LLC2,243,828$15.0M12.9%—
4FRANKLIN RESOURCES INC2,072,726$13.9M11.9%ADD +28.3%
5STATE STREET CORP964,670$6.5M5.6%—
6DIMENSIONAL FUND ADVISORS LP558,158$3.7M3.2%—
7BALYASNY ASSET MANAGEMENT L.P.557,654$3.7M3.2%—
8VANGUARD FIDUCIARY TRUST CO397,160$2.7M2.3%—
9VANGUARD PORTFOLIO MANAGEMENT LLC391,334$2.6M2.3%—
10MORGAN STANLEY224,041$1.5M1.3%TRIM -39.0%
11GOLDMAN SACHS GROUP INC178,726$1.2M1.0%—
12WELLINGTON MANAGEMENT GROUP LLP127,543$853.3K0.7%TRIM -32.8%
13BANK OF AMERICA CORP /DE/125,356$838.6K0.7%DOUBLED +356.5%
14RENAISSANCE TECHNOLOGIES LLC102,100$683.0K0.6%TRIM -29.7%
15CHARLES SCHWAB INVESTMENT MANAGEMENT INC97,139$649.9K0.6%TRIM -28.1%
16SUSQUEHANNA INTERNATIONAL GROUP, LLP96,500$645.6K0.6%—
17Nuveen, LLC72,712$486.4K0.4%—
18RHUMBLINE ADVISERS64,720$433.0K0.4%—
19MANUFACTURERS LIFE INSURANCE COMPANY, THE57,419$384.1K0.3%—
20AMERIPRISE FINANCIAL INC42,269$282.8K0.2%TRIM -64.5%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RENAISSANCE TECHNOLOGIES LLCTRIM145,200102,100-29.7%$683.0K2026-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCTRIM135,06397,139-28.1%$649.9K2026-Q1
Invesco Ltd.ADD27,28234,268+25.6%$229.3K2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDADD18,70027,000+44.4%$180.6K2026-Q1
Point72 Asset Management, L.P.TRIM54,69221,708-60.3%$145.2K2026-Q1
Trexquant Investment LPTRIM42,99820,998-51.2%$140.5K2026-Q1
ExodusPoint Capital Management, LPTRIM51,41917,955-65.1%$120.1K2026-Q1
CWM, LLCDOUBLED8114,018+395.4%$26.9K2026-Q1
FMR LLCTRIM8,1382,894-64.4%$19.4K2026-Q1
Rockefeller Capital Management L.P.DOUBLED1642,869+1649.4%$19.2K2026-Q1
Allworth Financial LPDOUBLED113745+559.3%$5.0K2026-Q1
PNC FINANCIAL SERVICES GROUP, INC.ADD4883+72.9%$555.002026-Q1
BANK OF AMERICA CORP /DE/DOUBLED36,183165,185+356.5%$900.3K2025-Q4
RENAISSANCE TECHNOLOGIES LLCADD97,608145,200+48.8%$791.3K2025-Q4
WELLS FARGO & COMPANY/MNADD31,71149,053+54.7%$267.3K2025-Q4
AMERIPRISE FINANCIAL INCTRIM120,74042,842-64.5%$233.5K2025-Q4
TD ASSET MANAGEMENT INCTRIM69,03040,502-41.3%$220.7K2025-Q4
DEUTSCHE BANK AG\TRIM45,45530,828-32.2%$168.0K2025-Q4
MetLife Investment Management, LLCADD19,35725,031+29.3%$136.4K2025-Q4
FMR LLCDOUBLED3,4678,138+134.7%$44.4K2025-Q4
Mirae Asset Global Investments Co., Ltd.ADD2,4023,086+28.5%$16.8K2025-Q4
Allworth Financial LPADD58113+94.8%$616.002025-Q4
PNC FINANCIAL SERVICES GROUP, INC.NEAR_EXIT35348-86.4%$262.002025-Q4
CWM, LLCTRIM1,305811-37.9%$4.002025-Q4
WELLINGTON MANAGEMENT GROUP LLPTRIM189,485127,312-32.8%$786.8K2025-Q3
8 unique insiders with 21 transactions. Net insider value: -$39.7M ($0.00 bought, $39.7M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 19, 2026Holles Natalie C.See RemarksAWARD600,118——
May 19, 2026Holles Natalie C.See RemarksAWARD2,169,103——
May 7, 2026Matrix Capital Management Company, LP10%+ OwnerSELL6,922,870$5.64$39.0M
Apr 16, 2026Kilroy ConorSee RemarksSELL11,738$7.02$82.4K
Mar 2, 2026Kilroy ConorSee RemarksAWARD62,339——
Mar 2, 2026Kilroy ConorSee RemarksAWARD112,661——
Mar 2, 2026de los Pinos ElisabetSee RemarksAWARD166,000——
Mar 2, 2026Gibney Anthony SSee RemarksAWARD71,245——
Mar 2, 2026Gibney Anthony SSee RemarksAWARD128,755——
Mar 2, 2026de los Pinos ElisabetSee RemarksAWARD249,000——
Mar 2, 2026Hopkins Janet JillChief Medical OfficerAWARD89,056——
Mar 2, 2026Hopkins Janet JillChief Medical OfficerAWARD160,944——
Mar 2, 2026Elazzouzi AmySenior Vice President, FinanceAWARD44,528——
Mar 2, 2026Elazzouzi AmySenior Vice President, FinanceAWARD80,472——
Mar 2, 2026Plavsic MarkChief Technology OfficerAWARD62,339——
Mar 2, 2026Plavsic MarkChief Technology OfficerAWARD112,661——
Feb 17, 2026Kilroy ConorSee RemarksSELL12,079$5.05$61.0K
Feb 17, 2026Plavsic MarkChief Technology OfficerSELL15,890$5.05$80.2K
Feb 17, 2026Hopkins Janet JillChief Medical OfficerSELL20,401$5.06$103.2K
Feb 17, 2026Elazzouzi AmySenior Vice President, FinanceSELL8,549$5.06$43.3K
Feb 17, 2026de los Pinos ElisabetSee RemarksSELL47,648$5.06$241.1K
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.4/10.
BEARISH 8-K 7/10
Aura Biosciences priced a massive underwritten public offering of 46.1M shares of common stock and p
May 5, 2026
NEUTRAL 8-K 5/10
Aura Biosciences announced a stock repurchase agreement with Matrix Capital to buy back up to 6.9M s
May 4, 2026
BEARISH 424B5 6/10
Aura Biosciences filed a preliminary prospectus supplement for an underwritten public offering of co
May 4, 2026
BULLISH 8-K 6/10
Aura Biosciences announced a CEO transition: founder Elisabet de los Pinos steps down and Natalie Ho
May 4, 2026
NEUTRAL DEFA14A 3/10
Aura Biosciences is holding its 2026 Annual Meeting where shareholders will vote to elect two Class
Apr 20, 2026
NEUTRAL 3/10
Aura Biosciences granted inducement equity awards to new CEO Natalie Holles, consisting of stock opt
May 19, 2026
BEARISH 7/10
Aura Biosciences closed an underwritten public offering of 46.1M shares and 3.8M pre-funded warrants
May 5, 2026
BEARISH 7/10
Aura Biosciences priced a large underwritten public offering of ~43.4M shares/pre-funded warrants at
May 4, 2026
BEARISH 5/10
Aura Biosciences announced an underwritten public offering of common stock and pre-funded warrants,
May 4, 2026
MIXED 5/10
Aura Biosciences announced the appointment of Natalie Holles as CEO and President, succeeding founde
May 4, 2026
MIXED 5/10
Aura Biosciences reported Q4 and full-year 2025 financial results, highlighting accelerated enrollme
Mar 30, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$18.80 mean target +193.3% upside Strong Buy (1.17)
$15.00 Low $24.00 High
MetricValue
Current Price$6.41
Target Low$15.00
Target Mean$18.80
Target Median$17.00
Target High$24.00
# Analysts5
RecommendationStrong Buy (1.17)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.38 $-0.50 $-0.30 20.2% +7.4% 2↑ 1↓ $0.0B 0.0% 4
Next Q
2026-09-30
 $-0.37 $-0.50 $-0.30 8.1% +6.4% 2↑ 1↓ $0.0B 0.0% 4
Current FY
2026-12-31
 $-1.59 $-2.00 $-1.41 9.4% +0.5% 2↑ 1↓ $0.0B 0.0% 4
Next FY
2027-12-31
 $-1.67 $-1.91 $-1.35 -4.6% -2.3% 1↑ 2↓ $0.0B 0.0% 4

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.375
7d ago$-0.375
30d ago$-0.405+0.030
60d ago$-0.405+0.030
90d ago$-0.458+0.083
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 29, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Mar 30, 2026 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263810092%
May 1, 20263810092%
Apr 1, 20263810092%
Mar 1, 20263810092%
Feb 1, 20263810092%
Jan 1, 20263810092%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 19, 2026
regulatory
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1I
May 12, 2026
other
Aura Biosciences to Participate in Upcoming Investor Conferences
<p align="justify">BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epJ_6n4KzuW5Vn8jW1W5fOWIcmEHZGWKehEJ
May 11, 2026
earnings
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data</em></p>
May 7, 2026
earnings_calendar
AURA Q1 2026 Earnings Before Market Open — 2026-05-07
May 5, 2026
offering
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precis
May 5, 2026
short_volume
Short Volume: AURA — 58.4% short (1.3M / 2.3M)
Short: 1,327,775 | Exempt: 48 | TRF Vol: 2,274,217 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 4, 2026
offering
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
<p>BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precis
May 4, 2026
offering
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
<p>BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precis
May 4, 2026
leadership
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
<p align="center"><em>Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointe
Mar 31, 2026
earnings_calendar
AURA Q4 2025 Earnings After Market Close — 2026-03-31
Mar 30, 2026
earnings
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
<p align="center"><em>Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance</em></p>